• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Stoke Therapeutics Inc.

    4/22/26 4:09:16 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STOK alert in real time by email
    DEFA14A 1 d79682ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    STOKE THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO

    Your Vote Counts! STOKE THERAPEUTICS, INC. 2026 Annual Meeting Vote by June 2, 2026 11:59 PM ET STOKE THERAPEUTICS, INC. 45 WIGGINS AVE. BEDFORD, MA 01730 V95129-P47897 You invested in STOKE THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 3, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 20, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your 16-digit control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and June 3, 2026 9:00 AM ET vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/STOK2026 *Please check the meeting materials for any special requirements for meeting attendance. 


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1. Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal. Nominees: For All 01) G. Clare Kahn, Ph.D. 02) Adrian Krainer, Ph.D. 03) Julie Anne Smith 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year For ending December 31, 2026. 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers. For NOTE: Stockholders may be asked to consider and vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V95130-P47897

    Get the next $STOK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STOK

    DatePrice TargetRatingAnalyst
    2/24/2026$40.00Outperform
    Wolfe Research
    2/5/2026$60.00Buy
    Guggenheim
    1/5/2026$35.00Buy
    Chardan Capital Markets
    7/18/2025$30.00Buy
    Jefferies
    12/20/2024$24.00Buy
    Chardan Capital Markets
    10/14/2024$18.00Outperform
    Leerink Partners
    3/26/2024Market Perform → Outperform
    TD Cowen
    11/20/2023Neutral
    JP Morgan
    More analyst ratings

    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kahn Clare

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    4/7/26 7:09:14 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Kahn Clare

    3 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    4/7/26 7:08:13 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Ticho Barry

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    4/3/26 4:12:37 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    SEC Filings

    View All

    SEC Form DEFA14A filed by Stoke Therapeutics Inc.

    DEFA14A - Stoke Therapeutics, Inc. (0001623526) (Filer)

    4/22/26 4:09:16 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Stoke Therapeutics Inc.

    DEF 14A - Stoke Therapeutics, Inc. (0001623526) (Filer)

    4/22/26 4:05:31 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Stoke Therapeutics Inc.

    8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)

    4/7/26 4:05:24 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Stoke Therapeutics with a new price target

    Wolfe Research initiated coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $40.00

    2/24/26 7:56:29 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets resumed coverage on Stoke Therapeutics with a new price target

    Chardan Capital Markets resumed coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $35.00

    1/5/26 9:19:09 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Leadership Updates

    Live Leadership Updates

    View All

    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p

    4/7/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

    – Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol

    9/4/24 8:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

    – Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently annou

    4/17/24 8:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Stoke Therapeutics Inc.

    SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 4:24:49 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:12 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Financials

    Live finance-specific insights

    View All

    Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

    – Global Phase 3 EMPEROR study patient recruitment ongoing in the U.S., UK, and Japan with more than 20 patients randomized to zorevunersen or sham; Study on track to complete enrollment in second half of 2026 – – As of September 30, 2025, the Company had $328.6 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 – – Webcast and conference call for analysts and investors at 4:30PM Eastern Time today – Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a fi

    11/4/25 4:01:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, November 4, 2025, at 4:30 p.m. ET, to discuss third quarter 2025 business and financial updates. The webcast will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the cal

    10/30/25 4:30:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    – First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome – – New 3-year zorevunersen OLE data provide additional support for disease modification: continuing and durable reductions in seizures and improvements in cognition and behavior and generally well tolerated – – Phase 1 study of STK-002 initiated in patients with Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder – – As of June 30, 2025, the Company had $355.0 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 and into launch readiness – – Webcast and conference call for analysts and investors a

    8/12/25 4:01:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on April 15, 2026, it granted stock options to purchase an aggregate of 129,565 shares of common stock to fourteen new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $35.54 per share, which is equal to the closing price o

    4/16/26 4:01:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:00 p.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke Therape

    4/8/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    The Credibility Filter Wall Street Uses to Sort Biotech Winners

    VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinical data[1]. That is not a coincidence. The IQVIA Institute's latest annual report found that biopharma dealmaking is now clustering around high value science and companies with credentialed pipelines[2]. It's becoming apparent that smart money is no longer chasing press releases, it's chasing invitations. Conference stage presentations from field defining researchers, peer reviewed journal publications, and stacked regulatory designations have become the fi

    4/8/26 9:15:00 AM ET
    $ANVS
    $ARQT
    $NTLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances